LY127935, a new beta-lactam antibiotic, versus Proteus, Klebsiella, Serratia, and Pseudomonas.
AUTOR(ES)
Flournoy, D J
RESUMO
One hundred eight clinical isolates of Proteus, Klebsiella, Serratia, and Pseudomonas spp. were tested in vitro against LY127935, cefamandole, cefoxitin, ticarcillin, carbenicillin, gentamicin, tobramycin, and amikacin by broth microdilution. The activities of LY127935 were greater than or equal to those of the other antimicrobial agents against Proteus vulgaris, Klebsiella pneumoniae, and Serratia marcescens. Inhibitions were greatest, however, for ticarcillin and carbenicillin versus Proteus morganii and gentamicin versus Pseudomonas aeruginosa.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=352921Documentos Relacionados
- LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.
- In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibiotic.
- LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.
- Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria.
- FL 1060: a new beta-lactam antibiotic with novel properties
